logo
KKR and Capital Group launch funds targeting blend of private, public credit

KKR and Capital Group launch funds targeting blend of private, public credit

Reuters29-04-2025

April 29 (Reuters) - KKR (KKR.N), opens new tab and Capital Group launched two funds on Tuesday, which would allow retail investors to invest in both public and private credit.
The funds, Capital Group KKR Core Plus+ and Capital Group KKR Multi-Sector+, will allocate 60% of their assets to public fixed income and the rest to private credit.
Private credit — loans typically made by non-bank institutions — have surged in popularity in recent years as banks retreat from riskier forms of lending.
Being relatively insulated from the volatility of public debt markets, private credit can be a crucial source of diversification for investors.
So far, however, these assets have mostly been limited to institutional investors.
"We are aiming to unlock the benefits of private investments for the 95% of individual investors who have not historically been able to invest in the private markets," KKR co-CEOs Joe Bae and Scott Nuttall said.
A report from Moody's earlier this year estimated the private credit market could grow to $3 trillion by 2028.
The new funds will allow investments starting at $1,000, lower than the typical minimums for such funds, to attract retail investors.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

KKR threat to NHS landlord: Don't give the barbarians a foothold in a sacred public service, says ALEX BRUMMER
KKR threat to NHS landlord: Don't give the barbarians a foothold in a sacred public service, says ALEX BRUMMER

Daily Mail​

timean hour ago

  • Daily Mail​

KKR threat to NHS landlord: Don't give the barbarians a foothold in a sacred public service, says ALEX BRUMMER

Freed from the proposed £4billion rescue of Thames Water, private equity barons KKR have come fizzing back with an upgraded offer for NHS and private healthcare landlords Assura. KKR's latest and final bid of £1.7billion is only marginally better than that from listed rival Primary Health Properties (PHP) but is being recommended by Assura's board. The battle isn't necessarily over, with PHP still looking at options and claiming Chancellor Rachel Reeves's bonanza spending on the NHS as an ally. As has become customary when listed companies seek to vanish from the London stock market, there is extensive waffle from Assura about careful evaluation and fiduciary duty. The latter is investment banker-speak for running up the white flag. In cash terms, the KKR offer, at 52.1p a share, is barely better than the 51.7p bid from PHP. A 39 per cent premium may seem wonderful but given the depressed state of share valuations in London and a recent tech offer with a 96 per cent premium, the KKR deal is hardly effervescent. There is no obligation for Assura to accept either deal. A braver board would have told the private equity plunderers to get lost. Instead, it chose to disparage the alternative 'merger' with PHP, claiming financial and execution risk. The board also argues that the PHP offer would diminish Assura's efforts to support investment in the NHS estate. Who is Assura kidding? KKR fears too much exposure to regulated British assets and the political risk which comes with it as we learned when it pulled out of the near-complete Thames Water deal. Assura also needs to remind itself of how private equity works. Load up target companies with debt, squeeze costs, do some clever financial engineering with the leverage, raise prices or rents and head for the hills. A Government which better understood how highly indebted deals work might be cautious. A reading of the Competition & Markets Authority's work on veterinary services, revealing how the cost to pet owners and farmers has escalated, illustrates the dangers. More market-based private medicine in the UK eases pressure on the NHS. But allowing the barbarians a foothold in a sacred service is unacceptable even if it's wrapped up with tinsel and a bow. Sign of the Zodiac This week's pandemic of bids for Britain's tech crown jewels and skin care specialists rightly has been accompanied by much handwringing. How is it that companies born and bred in UK science and tech struggle to develop into national champions? After all, the City is second only to New York as a financial centre and is home to one of the world's biggest collection of banks and a strong venture capital industry. There ought to be no bars to start-ups or smaller listed firms accessing capital. Freeing up pension funds, allowing them to be more adventurous, ought to help. But swift market access to funding and liquidity is the key. That is why the launch of Pisces, the London Stock Exchange's platform for 'intermittent' capital, a place to come to raise funding and then vanish behind a privacy wall, is an important innovation. Stock exchange group boss David Schwimmer has been promoting the concept for years but freeing it from the weeds of regulatory bureaucracy is not easy. The insistence on broad-based disclosure rules threatened to sideline it. So it is good to learn that the Financial Conduct Authority, in keeping with the growth agenda, has dropped onerous transparency requirements on the environment, shareholder transactions and director pay. These threatened to strangle Pisces at birth. Let the fundraising begin before the rush to the door of UK tech and AI becomes a stampede. Peer pressure It has become something of a thing for Chancellors to name-check colleagues when delivering grand financial statements to the Commons. Rachel Reeves set a record with her pledges to spend, spend, spend in Labour constituencies in the North, Midlands, Scotland and Wales. Lonely Weymouth was the only southern town to receive much of a mention. Unlike Southport, it already has a serviceable pier.

TRADING DAY Good vibrations turn sour
TRADING DAY Good vibrations turn sour

Reuters

timean hour ago

  • Reuters

TRADING DAY Good vibrations turn sour

ORLANDO, Florida, June 11 (Reuters) - TRADING DAY Making sense of the forces driving global markets By Jamie McGeever, Markets Columnist I'm excited to announce that I'm now part of Reuters Open Interest (ROI), an essential new source for data-driven, expert commentary on market and economic trends. You can find ROI on the Reuters website, and you can follow us on LinkedIn and X. The US and China have reached a trade deal, or at least agreed on the framework of a deal, which together with surprisingly soft U.S. inflation data, gave markets a lift on Wednesday. But Wall Street's gains were mild, and they were later wiped out by rising tensions in the Middle East. In my column today I look at the 'equity risk premium' and other metrics that suggest relative U.S. equity and bond valuations are getting very stretched. More on that below, but first, a roundup of the main market moves. If you have more time to read, here are a few articles I recommend to help you make sense of what happened in markets today. Today's Key Market Moves Good vibrations turn sour It's a "done" deal, according to U.S. President Donald Trump, although the he and Chinese leader Xi Jinping still have to finalize the wording of the trade agreement between the two superpowers and sign off on it. The main points of the deal appear to be: China will remove export restrictions on rare earth minerals and other key industrial components; U.S. tariffs on Chinese goods will total 55%; Chinese tariffs on U.S. goods will total 10%. Trump could not have been more enthusiastic in his praise for the agreement on Wednesday, and Commerce Secretary Howard Lutnick said 'deal after deal' with other countries will follow in the weeks ahead. Yet, judging by the relatively muted market reaction, investors are less enthused. And given the chaotic and unpredictable nature of the Trump administration's tariff announcements thus far, the irony of Treasury Secretary Scott Bessent calling on China to be a "reliable partner" in trade negotiations will not be lost on some observers. Especially, one suspects, in Beijing. Based on these proposed China levies, and with the US expected to conclude more trade deals in the coming weeks, the overall U.S. effective tariff rate will be lower than feared a couple of months ago. That's a relief. But the effective tariff rate of around 15% that many economists expect will still be significantly higher than the 2.5% rate at the end of last year, and would be the highest since the 1930s. Also, as the May inflation figures showed, tariffs have yet to be felt on prices. Investors - and Fed policymakers, who meet next week - are in a state of limbo. How will corporate profits and consumer spending be affected? What proportion of the tariffs will companies "swallow", and how much will they pass on to their customers? Zooming out, inflation appears to be cooling around the world, although this trend is expected to reverse once tariffs start to fuel higher goods price inflation. Figures on Wednesday showed that U.S. consumer inflation and Japanese wholesale inflation were lower than expected in May. These reports follow similar numbers from Europe recently, and China remains stuck in its battle against deflation. Next up is India, which releases consumer inflation figures on Thursday, which are expected to show annual inflation slowed to 3.0% in May, the lowest in more than six years. Another focus for investors on Thursday will be the auction of 30-year U.S. Treasury bonds. US stocks-bonds warnings flash amber again Calm has descended on U.S. markets following the 'Liberation Day' tariff turmoil of early April. But Wall Street's rally has revived questions about U.S. equity valuations, as stocks once again look super pricey compared to bonds. Since the chaotic days of early April, U.S. equities have rebounded fiercely, with the S&P 500 up 25%, putting the Shiller cyclically adjusted price-earnings (CAPE) ratio for the index in the 94th percentile going back to the 1950s, according to bond giant PIMCO. Stocks are looking expensive in absolute terms, and in relation to bonds. The equity risk premium (ERP), the difference between equity yields and bond yields, is near historically low levels. According to analysts at PIMCO, the ERP is now zero. The previous two times it fell to zero or below were in 1987 and 1996–2001. In both instances, the ultra-low ERP precipitated a steep equity drawdown and sharp fall in long-dated bond yields. "The U.S. equity risk premium ... is exceptionally low by historical standards," they wrote in their five-year outlook on Tuesday. "A mean reversion to a higher equity risk premium typically involves a bond rally, an equity sell-off, or both." But reversion to the mean doesn't just happen by magic. A catalyst is needed. Equities have recovered largely because they were oversold in April, trade tensions have been dialed down, and investors remain confident that Big Tech will drive solid AI-led earnings growth. So even though huge economic, trade, and policy risks continue to hang over markets, there is no sign of an imminent catalyst that would cause an equity market selloff. The flip side of equities looking expensive is that bonds look like a bargain. Indeed, the relative divergence between stocks and bonds is such that, by one measure, U.S. fixed income assets are the cheapest relative to equities in over half a century. Using national flow of funds data from the Federal Reserve, retired strategist Jim Paulsen calculates that the total market value of U.S. bonds as a percentage share of the total market value of U.S. equities is the lowest since the early 1970s. "Since the aggregate U.S. portfolio is currently aggressively positioned, investors may have far more capacity and desire to boost bond holdings in the coming years than most appreciate," Paulsen wrote last week. But bonds are 'cheap' for a reason. Washington's profligacy – the reason ratings agency Moody's recently stripped the U.S. of its triple-A credit rating – and inflation worries have kept yields stubbornly high. The term premium - the risk premium investors demand for holding long-term debt rather than rolling over short-dated loans - is the highest in over a decade, reflecting concerns about Uncle Sam's long-term fiscal health. And the diagnosis here shows no signs of improving. Trump's 'Big Beautiful Bill' is expected to add $2.4 trillion to the U.S. debt over the next decade, according to the nonpartisan Congressional Budget Office, likely putting more upward pressure on yields. Of course, equity investors do seem to be pricing in a very rosy scenario, and the past few months have shown how quickly the market landscape can change. The U.S. economy could weaken more than expected, the trade war could escalate, or there could be a geopolitical surprise that causes bond yields and equity prices to fall. Investors should therefore be mindful of the warnings being sent by ERPs and other absolute and relative valuation metrics. However, they should also remember that stretched valuations can get even more stretched. As the famous saying goes, markets can stay irrational longer than investors can remain solvent. What could move markets tomorrow? Opinions expressed are those of the author. They do not reflect the views of Reuters News, which, under the Trust Principles, opens new tab, is committed to integrity, independence, and freedom from bias.

Another two UK firms sell out to foreign bidders - but tech stars fend off predators
Another two UK firms sell out to foreign bidders - but tech stars fend off predators

Daily Mail​

timean hour ago

  • Daily Mail​

Another two UK firms sell out to foreign bidders - but tech stars fend off predators

Two more firms look set to leave the London stock market after takeover bids by foreign predators. GP surgery owner Assura has accepted a £1.7billion offer from US private equity giant KKR after a bidding war. And environmental consultancy Ricardo has been snapped up by rival WSP –owned by Canada's Genivar – in a £281million deal. WSP was previously listed in London before Genivar bought it in 2012. The latest deals come amid a mounting crisis for London amid a takeover frenzy. This week US chip giant Qualcomm bought Alphawave for £1.8billion while private equity group Advent is near a £3.7billion deal for scientific instrument maker Spectris. Meanwhile, US payments firm Corpay is circling UK fintech Alpha Group and Northern Ireland software company FD Technologies has accepted a £570million bid from private equity giant TA Associates. London has also been hit by defections as companies move listings to the US in search of higher valuations. And a lack of fresh listings means those companies are not being replaced. Accountant MHA is the only company worth more than £100million to have gone public on the London market so far in 2025. Assura, which owns doctors' surgeries, hospitals and hospices in the UK, recommended a 52.1p a share offer from KKR and Stonepeak to investors. KKR is one of the biggest private equity outfits in the US and Stonepeak is a New York investment firm. The decision knocks NHS landlord Primary Health Properties (PHP), which had briefly derailed KKR's takeover attempt, out of the running. PHP offered £1.68billion to buy Assura, while KKR's previous bid was £1.61billion – and its deal means Assura will leave London's stock market. In a merger with PHP, the FTSE 250 business would have become part of a publicly traded company, creating the eighth-largest UK-listed REIT. Assura chairman Ed Smith said: 'KKR and Stonepeak are highly experienced investors and I am confident that with their support, and the additional capital they will provide, Assura will continue to deliver high-quality healthcare infrastructure our communities need.' Assura had previously turned down bids of 46.2p and 43p per share from PHP, and a 48p proposal from KKR. UK tech starlets fend off private equity suitors The proposed takeovers of Assura and Ricardo came as two British tech starlets fended off private equity suitors. US buyout giant Bain Capital abandoned plans to acquire Craneware after the Edinburgh software firm rejected a £940million bid. And British private equity group ICG ditched its pursuit of data analytics firm GlobalData. It means the two tech companies will remain listed on the stock market in London – though other suitors may emerge. Shares in Craneware, which specialises in healthcare financial software for the US market, fell 0.8 per cent, or 15p, to 1990p while GlobalData dipped 10.1p per cent, or 17.5p, to 155p. Anxiety over Britain's status as a tech hub rose this week after US microchip giant Qualcomm swooped on London-listed Alphawave and fintech champion Wise announced plans to shift its main share listing to New York.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store